200 related articles for article (PubMed ID: 30988117)
1. Report on the 2018 Cancer, Autoimmunity, and Immunology Conference.
Curran CS; Sommers CL; Young HA; Bourcier K; Mancini M; Sharon E
J Immunol; 2019 May; 202(10):2823-2828. PubMed ID: 30988117
[TBL] [Abstract][Full Text] [Related]
2. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.
Khan S; Gerber DE
Semin Cancer Biol; 2020 Aug; 64():93-101. PubMed ID: 31330185
[TBL] [Abstract][Full Text] [Related]
3. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge.
Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C
Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Tison A; Quéré G; Misery L; Funck-Brentano E; Danlos FX; Routier E; Robert C; Loriot Y; Lambotte O; Bonniaud B; Scalbert C; Maanaoui S; Lesimple T; Martinez S; Marcq M; Chouaid C; Dubos C; Brunet-Possenti F; Stavris C; Chiche L; Beneton N; Mansard S; Guisier F; Doubre H; Skowron F; Aubin F; Zehou O; Roge C; Lambert M; Pham-Ledard A; Beylot-Barry M; Veillon R; Kramkimel N; Giacchero D; De Quatrebarbes J; Michel C; Auliac JB; Gonzales G; Decroisette C; Le Garff G; Carpiuc I; Vallerand H; Nowak E; Cornec D; Kostine M;
Arthritis Rheumatol; 2019 Dec; 71(12):2100-2111. PubMed ID: 31379105
[TBL] [Abstract][Full Text] [Related]
5. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
6. Treatment of rheumatic adverse events of cancer immunotherapy.
Reid P; Cappelli LC
Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101805. PubMed ID: 36539321
[TBL] [Abstract][Full Text] [Related]
7. 24th "Nantes Actualités en Transplantation" and 4th "LabEx Immunotherapy-Graft-Oncology" NAT and IGO Joint Meeting "New Horizons in Immunotherapy".
Joalland N; Ducoin K; Cadiou G; Rabu C; Guillonneau C
Front Immunol; 2021; 12():738312. PubMed ID: 34539674
[TBL] [Abstract][Full Text] [Related]
8. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
Abdel-Wahab N; Shah M; Lopez-Olivo MA; Suarez-Almazor ME
Ann Intern Med; 2018 Jan; 168(2):121-130. PubMed ID: 29297009
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy to treat malignancy in patients with pre-existing autoimmunity.
Boland P; Pavlick AC; Weber J; Sandigursky S
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303614
[TBL] [Abstract][Full Text] [Related]
11. Germline mechanisms of immunotherapy toxicities in the era of genome-wide association studies.
Gusev A
Immunol Rev; 2023 Sep; 318(1):138-156. PubMed ID: 37515388
[TBL] [Abstract][Full Text] [Related]
12. Supportive care for patients undergoing immunotherapy.
Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
[TBL] [Abstract][Full Text] [Related]
13. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
[TBL] [Abstract][Full Text] [Related]
14. Autoimmunity and Cancer, the Paradox Comorbidities Challenging Therapy in the Context of Preexisting Autoimmunity.
Valencia JC; Egbukichi N; Erwin-Cohen RA
J Interferon Cytokine Res; 2019 Jan; 39(1):72-84. PubMed ID: 30562133
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune complications of cancer immunotherapy.
Dhodapkar KM
Curr Opin Immunol; 2019 Dec; 61():54-59. PubMed ID: 31557690
[TBL] [Abstract][Full Text] [Related]
16. The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy.
Young A; Quandt Z; Bluestone JA
Cancer Immunol Res; 2018 Dec; 6(12):1445-1452. PubMed ID: 30510057
[TBL] [Abstract][Full Text] [Related]
17. Understanding adverse events of immunotherapy: A mechanistic perspective.
Burke KP; Grebinoski S; Sharpe AH; Vignali DAA
J Exp Med; 2021 Jan; 218(1):. PubMed ID: 33601411
[TBL] [Abstract][Full Text] [Related]
18. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
20. Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR.
Bayless NL; Bluestone JA; Bucktrout S; Butterfield LH; Jaffee EM; Koch CA; Roep BO; Sharpe AH; Murphy WJ; Villani AC; Walunas TL
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
